We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $1.85M
1-Year Est. Return 176.16%
This Fund
S&P 500
This Quarter Est. Return
-30.91%
1 Year Est. Return
+176.16%
3 Year Est. Return
+511.75%
5 Year Est. Return
+854.95%
10 Year Est. Return
+8,566.11%
AUM
$5.08M
AUM Growth
-$11.6M
Cap. Flow
-$8.83M
Cap. Flow %
-173.72%
Top 10 Hldgs %
99.52%
Holding
15
New
–
Increased
1
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$34.1K

Top Sells

Rank Stock Value
1
XERS icon
Xeris Biopharma Holdings
XERS
+$6.83M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$1.65M
3
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$324K
4
CBIO
Crescent Biopharma
CBIO
+$50.9K

Sector Composition

Rank Sector Weight
1 Healthcare 87.74%
2 Miscellaneous 7.36%
3 Financials 4.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RZLT icon
1
Rezolute
RZLT
$409M
$3.83M 75.28%
1,318,967
– –
GLD icon
2
SPDR Gold Trust
GLD
$145B
$374K 7.36%
1,298
+129
+11% +$34.1K
BRK.B icon
3
Berkshire Hathaway Class B
BRK.B
$1.1T
$249K 4.9%
467
-666
-59% -$324K
DFTX
4
Definium Therapeutics
DFTX
$5.41B
$199K 3.92%
34,073
– –
BCAX
5
Bicara Therapeutics
BCAX
$1.54B
$143K 2.81%
10,941
– –
CMPX icon
6
Compass Therapeutics
CMPX
$353M
$82.6K 1.63%
43,465
– –
LXEO icon
7
Lexeo Therapeutics
LXEO
$345M
$61.9K 1.22%
17,851
– –
KYTX icon
8
Kyverna Therapeutics
KYTX
$458M
$44.4K 0.87%
22,981
– –
CRDF icon
9
Cardiff Oncology
CRDF
$102M
$41.7K 0.82%
13,287
– –
IKT icon
10
Inhibikase Therapeutics
IKT
$333M
$35.9K 0.71%
16,393
– –
ACET icon
11
Adicet Bio
ACET
$90.8M
$13.2K 0.26%
1,093
– –
CNTX icon
12
Context Therapeutics
CNTX
$32.2M
$11.3K 0.22%
18,403
– –
CBIO
13
Crescent Biopharma
CBIO
$731M
– –
-2,036
Closed -$50.9K
SPY icon
14
State Street SPDR S&P 500 ETF Trust
SPY
$803B
– –
-2,823
Closed -$1.65M
XERS icon
15
Xeris Biopharma Holdings
XERS
$1.38B
– –
-2,015,157
Closed -$6.83M

Similar funds

1IC
1922 Investment Company Houston, Texas $1.89M AUM 15.39% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $1.91M AUM 81.42% 1-Year Est. Return
HGCK
HPC Germany & Co KG Potsdam, Germany $1.68M AUM 15.3% 1-Year Est. Return
CA
Cohalo Advisory Snoqualmie, Washington $1.65M AUM 11.44% 1-Year Est. Return
CAM
Creekmur Asset Management Morton, Illinois $2.07M AUM
FLC
Fifth Lane Capital Austin, Texas $1.63M AUM 7.3% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $1.56M AUM 25.68% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Caxton Corporation's Q1 2025 Portfolio in Review

As of Q1 2025, Caxton Corporation held 15 positions worth $5.08M, down 69% from $16.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation withdrew a net $8.83M in Q1 2025, closing 3 positions and reducing 1 holding. Its most notable exit was Xeris Biopharma Holdings, an estimated $6.83M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Caxton Corporation added an estimated $34.1K to SPDR Gold Trust.

  • Caxton Corporation added most to SPDR Gold Trust in Q1 2025, an estimated $34.1K increase.
  • Caxton Corporation's biggest Q1 2025 reduction was Berkshire Hathaway Class B, cutting an estimated $324K.
  • Caxton Corporation fully exited Xeris Biopharma Holdings in Q1 2025, selling an estimated $6.83M.
  • Caxton Corporation's ten largest holdings make up 100% of its $5.08M portfolio in Q1 2025.
  • Caxton Corporation opened 0 new positions and closed 3 in Q1 2025.
  • Caxton Corporation's portfolio value fell 69% quarter-over-quarter to $5.08M.

Based on Caxton Corporation's 13F filing for Q1 2025, filed 15 May 2025.